These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 16353599

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Beta-agonists as antiobesity, antidiabetic and nutrient partitioning agents.
    Yen TT.
    Obes Res; 1995 Nov; 3 Suppl 4():531S-536S. PubMed ID: 8697054
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Up-regulation of a thermogenesis-related gene (UCP1) and down-regulation of PPARgamma and aP2 genes in adipose tissue: possible features of the antiobesity effects of a beta3-adrenergic agonist.
    Margareto J, Larrarte E, Marti A, Martinez JA.
    Biochem Pharmacol; 2001 Jun 15; 61(12):1471-8. PubMed ID: 11377376
    [Abstract] [Full Text] [Related]

  • 5. Beta 3-adrenoceptor agonists as anti-diabetic and anti-obesity drugs in humans.
    de Souza CJ, Burkey BF.
    Curr Pharm Des; 2001 Sep 15; 7(14):1433-49. PubMed ID: 11472270
    [Abstract] [Full Text] [Related]

  • 6. Advances in pharmacotherapy for obesity.
    Carruba M, Tomello C, Briscini L, Nisoli E.
    Int J Obes Relat Metab Disord; 1998 Aug 15; 22 Suppl 1():S13-6; discussion S17. PubMed ID: 9758239
    [Abstract] [Full Text] [Related]

  • 7. [Obesity: a review of currently used antiobesity drugs and new compounds in clinical development].
    Zieba R.
    Postepy Hig Med Dosw (Online); 2007 Oct 19; 61():612-26. PubMed ID: 17971763
    [Abstract] [Full Text] [Related]

  • 8. Physiology and pathophysiology of the β3-adrenergic receptor.
    Yang LK, Tao YX.
    Prog Mol Biol Transl Sci; 2019 Oct 19; 161():91-112. PubMed ID: 30711031
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Translational Pharmacology and Physiology of Brown Adipose Tissue in Human Disease and Treatment.
    Larson CJ.
    Handb Exp Pharmacol; 2019 Oct 19; 251():381-424. PubMed ID: 30689089
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes.
    Hu B, Jennings LL.
    Prog Med Chem; 2003 Oct 19; 41():167-94. PubMed ID: 12774694
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M, Troskot R.
    Minerva Endocrinol; 2015 Mar 19; 40(1):71-83. PubMed ID: 25366984
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress.
    Arch JR.
    Eur J Pharmacol; 2002 Apr 12; 440(2-3):99-107. PubMed ID: 12007528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.